Schr枚dinger Announces Discontinuation of SGR-2921 Program
Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schr枚dinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had demonstrated that CDC7 inhibition resulted in monotherapy and combination anti-leukemic responses in patient-derived AML models, suggesting that SGR-2921 could ultimately be used in combination with standard of care agents.
鈥淧atient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients,鈥� stated Margaret Dugan, M.D., chief medical officer at Schr枚dinger. 鈥淲e had hoped to advance this investigational agent for acute myeloid leukemia as relapse rates are high, the disease progresses rapidly and there are limited therapies available. We are very grateful to the investigators, patients and families who have participated in this clinical study.鈥�
About Schr枚dinger
Schr枚dinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schr枚dinger鈥檚 software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schr枚dinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schr枚dinger has approximately 800 employees operating from 15 locations globally. To learn more, visit , follow us on and , or visit our blog, .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to the benefits of its computational platform. Statements including words such as 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schr枚dinger鈥檚 current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schr枚dinger鈥檚 control, including the uncertainties inherent in drug development, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical and early clinical studies will be predictive of the results of later preclinical studies and clinical trials, whether initial data from clinical results will be predictive of the final results of the clinical trials, uncertainties associated with the regulatory review of clinical trials, and the ability to retain and hire key personnel and other risks detailed under the caption 鈥淩isk Factors鈥� and elsewhere in the company鈥檚 Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 6, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schr枚dinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
View source version on businesswire.com:
Jaren Madden (Investors and Media)
[email protected]
617-286-6264
Matthew Luchini (Investors)
[email protected]
917-719-0636
Allie Nicodemo (Media)
[email protected]
617-356-2325
Source: Schr枚dinger
